Browse > Article
http://dx.doi.org/10.3345/kjp.2012.55.2.48

Clinical and genetic characteristics of Gaucher disease according to phenotypic subgroups  

Lee, Ju-Young (Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine)
Lee, Beom-Hee (Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine)
Kim, Gu-Hwan (Medical Genetics Center, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine)
Jung, Chang-Woo (Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine)
Lee, Jin (Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine)
Choi, Jin-Ho (Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine)
Yoo, Han-Wook (Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine)
Publication Information
Clinical and Experimental Pediatrics / v.55, no.2, 2012 , pp. 48-53 More about this Journal
Abstract
Purpose: Gaucher disease is caused by a ${\beta}$-glucocerebrosidase (GBA) deficiency. The aim of this study is to investigate the clinical and genetic characteristics according to subtypes of Gaucher disease in the Korean population. Methods: Clinical findings at diagnosis, $GBA$ mutations, and clinical courses were reviewed in 20 patients diagnosed with Gaucher disease. Results: Eleven patients were diagnosed with non-neuronopathic type, 2 with acute neuronopathic type, and 7 with chronic neuronopathic type. Most patients presented with hepatosplenomegaly, thrombocytopenia, and short stature. In the neuronopathic group, variable neurological features, such as seizure, tremor, gaze palsy, and hypotonia, were noted at age $8.7{\pm}4.3$ years. B cell lymphoma, protein-losing enteropathy, and hydrops fetalis were the atypical manifestations. Biomarkers, including chitotriosidase, acid phosphatase, and angiotensin-converting enzyme, increased at the initial evaluation and subsequently decreased with enzyme replacement treatment (ERT). The clinical findings, including hepatosplenomegaly, thrombocytopenia, and skeletal findings, improved following ERT, except for the neurological manifestations. L444P was the most common mutation in our cohort. One novel mutation, R277C, was found. Conclusion: Although the clinical outcome for Gaucher disease improved remarkably following ERT, the outcome differed according to subtype. Considering the high proportion of the neuronopathic form in the Korean population, new therapeutic strategies targeting the central nervous system are needed, with the development of a new scoring system and biomarkers representing clinical courses in a more comprehensive manner.
Keywords
Neuronopathic Gaucher disease; Non-neuronopathic Gaucher disease; GBA gene; Mutation;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Grigorescu Sido P, Drugan C, Cret V, Al-Kzouz C, Denes C, Coldea C, et al. Outcome of enzyme replacement therapy in patients with Gaucher disease type I. The Romanian experience. J Inherit Metab Dis 2007;30: 783-9.   DOI   ScienceOn
2 vom Dahl S, Mengel E. Lysosomal storage diseases as differential diagnosis of hepatosplenomegaly. Best Pract Res Clin Gastroenterol 2010;24:619-28.   DOI   ScienceOn
3 Hollak CE, van Weely S, van Oers MH, Aerts JM. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest 1994;93:1288-92.   DOI   ScienceOn
4 Grace ME, Balwani M, Nazarenko I, Prakash-Cheng A, Desnick RJ. Type 1 Gaucher disease: null and hypomorphic novel chitotriosidase mutations-implications for diagnosis and therapeutic monitoring. Hum Mutat 2007;28:866-73.   DOI   ScienceOn
5 Dodelson de Kremer R, Paschini de Capra A, Angaroni CJ, Giner de Ayala A. Plasma chitotriosidase activity in Argentinian patients with Gaucher disease, various lysosomal diseases and other inherited metabolic disorders. Medicina (B Aires) 1997;57:677-84.
6 Charles AS, Michael JB. Defects in metabolism of lipids. In: Kilegman RM, Behrman RE, Jenson HB, Stanton B, editors. Nelson textbook of pediatrics. 18th ed. Philadelphia: WB Saunders Co., 2007:595-7.
7 Brady RO, Kanfer JN, Shapiro D. Metabolism of glucocerebrosides. II. Evidence of an enzymatic deficiency in Gaucher's disease. Biochem Biophys Res Commun 1965;18:221-5.   DOI   ScienceOn
8 Barneveld RA, Keijzer W, Tegelaers FP, Ginns EI, Geurts van Kessel A, Brady RO, et al. Assignment of the gene coding for human beta-glucocerebrosidase to the region q21-q31 of chromosome 1 using monoclonal antibodies. Hum Genet 1983;64:227-31.   DOI   ScienceOn
9 Lam KW, Li CY, Yam LT, Smith RS, Hacker B. Comparison of prostatic and nonprostatic acid phosphatase. Ann N Y Acad Sci 1982;390:1-15.   DOI
10 Zimran A, Kay A, Gelbart T, Garver P, Thurston D, Saven A, et al. Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients. Medicine (Baltimore) 1992;71:337-53.   DOI   ScienceOn
11 Cabrera-Salazar MA, O'Rourke E, Henderson N, Wessel H, Barranger JA. Correlation of surrogate markers of Gaucher disease. Implications for long-term follow up of enzyme replacement therapy. Clin Chim Acta 2004;344:101-7.   DOI   ScienceOn
12 Kundson AG, Kaplan WD. Genetics of the sphingolipidosis. In: Aronson SM, Volk BW, editors. Cerebral sphingolipidoses: a symposium on Tay- Sachs' disease and allied disorders. New York: Academic Press, 1962:395-411.
13 Balicki D, Beutler E. Gaucher disease. Medicine (Baltimore) 1995;74:305-   DOI   ScienceOn
14 Horowitz M, Zimran A. Mutations causing Gaucher disease. Hum Mutat 1994;3:1-11.   DOI   ScienceOn
15 Barranger JA, Rice E, Sakallah SA, Sansieri C, Mifflin TE, Cooper DL. Enzymatic and molecular diagnosis of Gaucher disease. Clin Lab Med 1995;15:899-913.
16 Jmoudiak M, Futerman AH. Gaucher disease: pathological mechanisms and modern management. Br J Haematol 2005;129:178-88.   DOI   ScienceOn
17 Patterson MC, Horowitz M, Abel RB, Currie JN, Yu KT, Kaneski C, et al. Isolated horizontal supranuclear gaze palsy as a marker of severe systemic involvement in Gaucher's disease. Neurology 1993;43:1993-7.   DOI   ScienceOn
18 Beutler E, Gelbart T. Hematologically important mutations: Gaucher disease. Blood Cells Mol Dis 1997;23:2-7.   DOI   ScienceOn
19 Jeong SY, Park SJ, Kim HJ. Clinical and genetic characteristics of Korean patients with Gaucher disease. Blood Cells Mol Dis 2011;46:11-4.   DOI   ScienceOn
20 Choi HS, Kim SH, Ida H, Kim HJ. The clinical characteristics and gene analysis of Korean Gaucher disease with central nervous system involvement. J Korean Pediatr Soc 2000;43:611-8.
21 Martins AM, Valadares ER, Porta G, Coelho J, Semionato Filho J, Pianovski MA, et al. Recommendations on diagnosis, treatment, and monitoring for Gaucher disease. J Pediatr 2009;155(4 Suppl):S10-8.   DOI
22 Starzyk K, Richards S, Yee J, Smith SE, Kingma W. The long-term international safety experience of imiglucerase therapy for Gaucher disease. Mol Genet Metab 2007;90:157-63.   DOI   ScienceOn
23 Chen M, Wang J. Gaucher disease: review of the literature. Arch Pathol Lab Med 2008;132:851-3.